Shattuck Labs Q2 loss reaches $15.2 million

• Shattuck Labs reported a Q2 2026 net loss of $15.2 million with no revenue, while cash and investments reached $208.3 million.
• No verified post-results STTK trade was available, with the latest market price at $7.14.
• Shattuck expects its RECEPTIVE-CD1 Phase 2b Crohn’s disease trial to begin in Q3 2026, with 12-week data expected in H1 2028.

Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.

The loss increased slightly from $14.8 million in Q1, while cash and investments rose from $90.4 million to $208.3 million.

Phase 1 data showed 3.7% antidrug antibody incidence, blockade beyond three months at doses of at least 1 mg/kg and no DR3 agonism.

Shattuck expects the roughly 232-patient RECEPTIVE-CD1 Phase 2b trial to start in Q3 2026, with 12-week endoscopic-response data in H1 2028.

Shattuck is also advancing DR3 x IL-23R bispecific SL-846 through GLP toxicology and expects to begin Phase 1 development in 2027.

The company strengthened its balance sheet through an upsized June equity offering and warrant exercises, with management expecting funding to extend into 2029.